Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Results From Thai HIV/AIDS Vaccine Trial Scheduled to Be Released in July

May 2, 2007

The Thai Ministry of Public Health on Tuesday announced that results from the latest phase of an HIV/AIDS vaccine clinical trial are scheduled to be released in July, Thai News Agency/MCOT reports (Thai News Agency/MCOT, 5/1). The NIH-funded trial is testing Brisbane, Calif.-based biotechnology company VaxGen's AIDS vaccine AIDSVAX in conjunction with Sanofi Pasteur's ALVAC among 16,000 HIV-negative volunteers from Thailand's Rayong and Chon Buri provinces. In the trial, AIDSVAX is used as a booster for the ALVAC vaccine. Each volunteer for the trial, which is scheduled to end in 2009, will be followed up for at least three-and-a-half years. Some researchers have questioned the validity, science, ethics and potential efficacy of the trial. A group of 22 prominent AIDS researchers in the Jan. 16, 2004, issue of the journal Science wrote that the study should be halted because of its high cost and because the two vaccines used by themselves in Phase I and Phase II clinical trials were ineffective in preventing HIV transmission (Kaiser Daily HIV/AIDS Report, 5/22/06).

According to Thawat Suntrajarn, director-general of Thailand's Department of Disease Control, the health ministry last week discussed the results with several U.S. government agencies and companies to prepare a response plan to handle any emergencies that arise after the results are released. NIH and the vaccine makers will meet in Thailand in June to determine the next steps in the process, Thawat said. If the test results find the vaccine has an efficacy of 80% or higher, the vaccine will enter commercial production. The vaccine will be tested for another two years if it is found to have an efficacy of between 50% and 79%, and the trial will be discontinued if the efficacy is below 50%, according to Thai News Agency/MCOT (Thai News Agency/MCOT, 5/1).

Back to other news for May 2007

Advertisement

Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2007 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement